Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1299-1312

  Kalimutho, Murugan ^a   Minutolo, Antonella ^a,b   Grelli, Sandro ^a,b   Formosa, Amanda ^a   Sancesario, Giulia ^a   Valentini, Alessandra ^a   Federici, Giorgio ^a   Bernardini, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Apoptosis; CRC; miR 34a; Oxaliplatin; p53; Platinum; Satraplatin

Indexed keywords

CASPASE 8; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1; FAS ANTIGEN; MESSENGER RNA; MICRORNA; MICRORNA 34A; OXALIPLATIN; PROTEIN P53; SATRAPLATIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL LEVEL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; G2 PHASE; HCT116 CELLS; HT29 CELLS; HUMANS; MICRORNAS; MUTATION; ORGANOPLATINUM COMPOUNDS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959618716     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1428-4     Document Type: Article

References (41)

1. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30 (Pubitemid 41095110)
2. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48:398-406
3. Desoize B, Madoulet C (2002) Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42:317-325 (Pubitemid 34615692)
4. Gourdier I, Del Rio M, Crabbe L, Candeil L, Copois V, Ychou M, Auffray C, Martineau P, Mechti N, Pommier Y, Paul B (2002) Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529:232-236
5. Chen CC, Chen LT, Tsou TC, Pan WY, Kuo CC et al (2007) Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br J Cancer 97:334-344
6. Lane DP (1992) p53, guardian of the genome. Nature 358:15-16
7. Arango D, Wilson AJ, Shi Q et al (2004) Molecular mechanism of action and prediction of response to oxaliplatin in colorectal cancer. Br J Cancer 91:1931-1946 (Pubitemid 40065523)
8. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, Perego P (2003) Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3:21-29 (Pubitemid 36119418)
9. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I (2001) Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61:577-581 (Pubitemid 32128617)
10. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT (1997) Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 89:783-789 (Pubitemid 27242279)
11. Peter ME, Legembre P, Barnhart BC (2008) Does CD95 have tumor promoting activities? Biochim Biophys Acta 1755:25-36
12. McKeage MJ (2005) New-generation platinum drugs in the treatment of cisplatin resistant cancers. Expert Opin Investig Drugs 14(8):1033-1046
13. Kelland LR, Abel G, McKeage MJ et al (1993) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 53:2581-2586 (Pubitemid 23168026)
14. Sharp SY, Rogers PM, Kelland LR (1995) Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine platinum (IV) (JM-216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1(9):981-989
15. Moore MR, Troner MB, DeSimone P et al (1986) Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a southeastern cancer study group trial. Cancer Treat Res 70:541-542 (Pubitemid 16116470)
16. McKeage MJ, Raynaud F, Ward J et al (1997) Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15:2691-2700 (Pubitemid 27289902)
17. Fokkema E, Groen HJM, Bauer J et al (1999) Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 17:3822-3827
18. Fink D, Nebel S, Aebi S et al (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886 (Pubitemid 26374423)
19. Fokkema E, Groen HJM, Helder MN et al (2002) JM216, JM118, and cisplatin induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63:1989-1996 (Pubitemid 34687040)
20. Sternberg CN, Whelan P, Hetherington P et al (2005) Phase III trial of satraplatin, an oral platinum plus prednisone versus prednisone alone in patients with hormone-resistant prostate cancer. Oncology 68:2-9 (Pubitemid 40675002)
21. Vaisman A, Lim SE, Patrick SM et al (1999) Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry 38:11026-11039
22. Masters JRW, Twentyman P, Arlett C et al (2000) UKCCCR guidelines for the use of cell lines in cancer research. British J of Cancer 82(9):1495-1509 (Pubitemid 30204353)
23. Matteucci C, Grelli S, De Smaele E, Fontana C, Mastino A (1999) Identification of nuclei from apoptotic, necrotic, and viable lymphoid cells by using multiparameter flow cytometry. Cytometry 35:145-153 (Pubitemid 29053251)
24. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55(4):611-622
25. Blijham GH (1991) Chemotherapy of colorectal cancer. Anti-cancer Drugs 2:233-245
26. De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947 (Pubitemid 30644117)
27. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR (1992) Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complexes exhibiting selective cytotoxicity to intrinsic cisplatin resistant human ovarian carcinoma cell lines. Cancer Res 52:822-828
28. Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, Rattel B, Caligiuri M (2007) Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 60(4):589-600 (Pubitemid 47084271)
29. Ormerod M, O'Neill C, Robertson D, Kelland LR, Harrap KR (1996) Cis-diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37:463-471
30. Vaisman A, Varchenko M, Said I, Chaney SG (1997) Cell cycle changes associated with the formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27:54-64 (Pubitemid 27059782)
31. Zaffaroni N, Silvestrini R, Orlandi L, Bearzatto A, Gornati D, Villa R (1998) The induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin, sensitive and resistant human ovarian cancer cells. Br J Cancer 77:1378-1385 (Pubitemid 28190736)
32. O'Neill CF, Ormerod MG, Robertson D, Titley JC, Cumber-Walsweer Y, Kelland LR (1996) Apoptotic and non apoptotic cell death induced by cis and trans analogues of a novel ammine (cyclohexylamine) dihydroxodichloroplatinum (IV) complex. Br J Cancer 74:1037-1045 (Pubitemid 26333903)
33. Sorenson CM, Eastman A (1998) Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 48:6703-6707
34. Di Paola R (2002) To arrest or not to G2-M cell cycle arrest. Clin Can Res 8:3311-3314
35. Dan S, Yamori T (2001) Repression of cyclin B1 expression after treatment with Adriamycin, but not cisplatin in human lung cancer A549 cells. Biochem Biophys Res Commun 280:861-867 (Pubitemid 32924511)
36. Voland C, Bord A, Peleraux A, Penarier G, Carriere D, Galiegue S, Cvitkovic E, Jbilo O, Casellas P (2006) Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 5:2149-2157 (Pubitemid 44530450)
37. waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. Mol Cancer Ther 4:1585-1594
38. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI (2004) Enhanced oxaliplatin-induced apoptosis following antisense Bclxl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3:169-178 (Pubitemid 39193691)
39. Marchetti P, Galla DA, Russo FP, Ricevuto E, Flati V, Porzio G, Ficorella C, Cifone MG (2004) Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line. Anticancer Res 24:219-226 (Pubitemid 38279711)
40. Rossi L, Bonmassar E, Faraoni I (2007) Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res 56(3):248-253 (Pubitemid 47321208)
41. Hermeking H (2007) p53 enters the microRNA world. Cancer Cell 12(5):414-418